Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Vandoeuvre Les Nancy – page 29

584 clinical trials in Vandoeuvre Les Nancy, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Vandoeuvre Les Nancy at a glance
584
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

584 trials in Vandoeuvre Les Nancy

Open in trial search

Gastric cancer+2

Not yet recruiting

Study of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Institut Curie

Factor VIII deficiency+1

Not yet recruiting

Study on Joint Health in Hemophilia A and B Patients Using Efmoroctocog Alfa or Eftrenonacog Alfa

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efmoroctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Study on the Effectiveness of Paclitaxel, Carboplatin, and Durvalumab for Patients with Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Atrial fibrillation

Not yet recruiting

Study on Spironolactone for Maintaining Sinus Rhythm in Hypertensive Patients with Atrial Fibrillation and Preserved Heart Function

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Micronised Spironolactone
  • Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Study of Rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lanifibranor
  • Sponsor:Inventiva

Colitis ulcerative

Not recruiting

Study of Tulisokibart for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Prometheus Biosciences Inc.

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Vandoeuvre Les Nancy

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including head and neck squamous cell carcinoma, multiple myeloma, and prostate cancer. Studies evaluate new therapeutic approaches and diagnostic methods.

  • Advanced cancer treatments
  • Therapeutic combinations
  • Survival outcomes

Several trials investigate novel drug combinations and targeted therapies for improving patient outcomes.

02 Autoimmune Conditions

Comprehensive research into inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Studies explore innovative treatments including microbiota transplantation and new biological therapies.

  • Disease management
  • Treatment efficacy
  • Long-term outcomes

Trials aim to develop more effective maintenance therapies and improve quality of life for patients.

03 Neurological Disorders

Groundbreaking research in multiple sclerosis treatment, including both progressive and relapsing forms. Studies evaluate new therapeutic approaches and disease progression markers.

  • Disease modification
  • Treatment safety
  • Clinical outcomes

Focus on developing innovative treatments for better management of neurological conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.